Comparing the Diagnostic Performance of [18F]PSMA‐1007 With [68Ga]Ga‐PSMA‐11 in PET/CT Imaging and Staging of Recurrent Prostate Cancer
ABSTRACT PET/CT has become the reference standard imaging modality for diagnosing prostate cancer because of its ability to target prostate‐specific membrane antigen (PSMA), a protein specific to prostate cells. [68Ga]Ga‐PSMA‐11 was a major advance, but limitations such as a short lifespan and image...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-03-01
|
| Series: | Medicine Advances |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/med4.70006 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850061856268353536 |
|---|---|
| author | Negar Abdi Miad Alsulami Hamid Ghaznavi |
| author_facet | Negar Abdi Miad Alsulami Hamid Ghaznavi |
| author_sort | Negar Abdi |
| collection | DOAJ |
| description | ABSTRACT PET/CT has become the reference standard imaging modality for diagnosing prostate cancer because of its ability to target prostate‐specific membrane antigen (PSMA), a protein specific to prostate cells. [68Ga]Ga‐PSMA‐11 was a major advance, but limitations such as a short lifespan and image blurring led to the introduction of [18F]PSMA‐1007, which offers advantages such as a longer lifespan and clearer images. This study aimed to compare the effectiveness of [18F]PSMA‐1007 and [68Ga]Ga‐PSMA‐11 in the detection and staging of recurrent prostate cancer because there is currently insufficient evidence to conclude that one PSMA‐radiotracer is better than the other. Both 68Ga and 18F‐labeled PSMA‐radiotracers have similar detection rates in patients. Therefore, more investigation is required to authoritatively conclude which radiotracer results in optimal performance for diagnosing prostate cancer lesions on PET/CT. In this narrative review, we focus on comparing the effectiveness of [18F]PSMA‐1007 with that of [68Ga]Ga‐PSMA‐11 in the detection of recurrent prostate cancer and determination of its stage. We found that [18F]PSMA‐1007 and [68Ga]Ga‐PSMA‐11 showed similar diagnostic performance, with [18F]PSMA‐1007 having slightly higher sensitivity for primary and metastatic recurrent prostate cancer. However, a lack of statistical significance in the differences between the two radiotracers indicates comparable diagnostic accuracy, enabling their interchangeable use based on availability and cost efficiency. |
| format | Article |
| id | doaj-art-116703e8dced4f22aa82a6793eab5ab1 |
| institution | DOAJ |
| issn | 2834-4391 2834-4405 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Medicine Advances |
| spelling | doaj-art-116703e8dced4f22aa82a6793eab5ab12025-08-20T02:50:05ZengWileyMedicine Advances2834-43912834-44052025-03-013191910.1002/med4.70006Comparing the Diagnostic Performance of [18F]PSMA‐1007 With [68Ga]Ga‐PSMA‐11 in PET/CT Imaging and Staging of Recurrent Prostate CancerNegar Abdi0Miad Alsulami1Hamid Ghaznavi2Department of Radiology Kurdistan University of Medical Sciences Sanandaj IranMolecular Imaging & Nuclear Medicine Section King Abdulaziz Medical City & King Abdullah Specialist Children's Hospital Riyadh Saudi ArabiaDepartment of Computer Engineering Social and Biological Network Analysis Laboratory (SBNA) University of Kurdistan Sanandaj IranABSTRACT PET/CT has become the reference standard imaging modality for diagnosing prostate cancer because of its ability to target prostate‐specific membrane antigen (PSMA), a protein specific to prostate cells. [68Ga]Ga‐PSMA‐11 was a major advance, but limitations such as a short lifespan and image blurring led to the introduction of [18F]PSMA‐1007, which offers advantages such as a longer lifespan and clearer images. This study aimed to compare the effectiveness of [18F]PSMA‐1007 and [68Ga]Ga‐PSMA‐11 in the detection and staging of recurrent prostate cancer because there is currently insufficient evidence to conclude that one PSMA‐radiotracer is better than the other. Both 68Ga and 18F‐labeled PSMA‐radiotracers have similar detection rates in patients. Therefore, more investigation is required to authoritatively conclude which radiotracer results in optimal performance for diagnosing prostate cancer lesions on PET/CT. In this narrative review, we focus on comparing the effectiveness of [18F]PSMA‐1007 with that of [68Ga]Ga‐PSMA‐11 in the detection of recurrent prostate cancer and determination of its stage. We found that [18F]PSMA‐1007 and [68Ga]Ga‐PSMA‐11 showed similar diagnostic performance, with [18F]PSMA‐1007 having slightly higher sensitivity for primary and metastatic recurrent prostate cancer. However, a lack of statistical significance in the differences between the two radiotracers indicates comparable diagnostic accuracy, enabling their interchangeable use based on availability and cost efficiency.https://doi.org/10.1002/med4.70006[18F]PSMA‐1007[68Ga]Ga‐PSMA‐11PET/CT imagingprostate cancer |
| spellingShingle | Negar Abdi Miad Alsulami Hamid Ghaznavi Comparing the Diagnostic Performance of [18F]PSMA‐1007 With [68Ga]Ga‐PSMA‐11 in PET/CT Imaging and Staging of Recurrent Prostate Cancer Medicine Advances [18F]PSMA‐1007 [68Ga]Ga‐PSMA‐11 PET/CT imaging prostate cancer |
| title | Comparing the Diagnostic Performance of [18F]PSMA‐1007 With [68Ga]Ga‐PSMA‐11 in PET/CT Imaging and Staging of Recurrent Prostate Cancer |
| title_full | Comparing the Diagnostic Performance of [18F]PSMA‐1007 With [68Ga]Ga‐PSMA‐11 in PET/CT Imaging and Staging of Recurrent Prostate Cancer |
| title_fullStr | Comparing the Diagnostic Performance of [18F]PSMA‐1007 With [68Ga]Ga‐PSMA‐11 in PET/CT Imaging and Staging of Recurrent Prostate Cancer |
| title_full_unstemmed | Comparing the Diagnostic Performance of [18F]PSMA‐1007 With [68Ga]Ga‐PSMA‐11 in PET/CT Imaging and Staging of Recurrent Prostate Cancer |
| title_short | Comparing the Diagnostic Performance of [18F]PSMA‐1007 With [68Ga]Ga‐PSMA‐11 in PET/CT Imaging and Staging of Recurrent Prostate Cancer |
| title_sort | comparing the diagnostic performance of 18f psma 1007 with 68ga ga psma 11 in pet ct imaging and staging of recurrent prostate cancer |
| topic | [18F]PSMA‐1007 [68Ga]Ga‐PSMA‐11 PET/CT imaging prostate cancer |
| url | https://doi.org/10.1002/med4.70006 |
| work_keys_str_mv | AT negarabdi comparingthediagnosticperformanceof18fpsma1007with68gagapsma11inpetctimagingandstagingofrecurrentprostatecancer AT miadalsulami comparingthediagnosticperformanceof18fpsma1007with68gagapsma11inpetctimagingandstagingofrecurrentprostatecancer AT hamidghaznavi comparingthediagnosticperformanceof18fpsma1007with68gagapsma11inpetctimagingandstagingofrecurrentprostatecancer |